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The impact of the adequacy of empirical therapy on outcome for patients with bloodstream infections (BSI) is key for determin-
ing whether adequate empirical coverage should be prioritized over other, more conservative approaches. Recent systematic
reviews outlined the need for new studies in the field, using improvedmethodologies. We assessed the impact of inadequate
empirical treatment on the mortality of patients with BSI in the present-day context, incorporating recent methodological rec-
ommendations. A prospective multicenter cohort including all BSI episodes in adult patients was performed in 15 hospitals in
Andalucía, Spain, over a 2-month period in 2006 to 2007. The main outcome variables were 14- and 30-day mortality. Adjusted
analyses were performed bymultivariate analysis and propensity score-based matching. Eight hundred one episodes were in-
cluded. Inadequate empirical therapy was administered in 199 (24.8%) episodes; mortality at days 14 and 30 was 18.55% and
22.6%, respectively. After controlling for age, Charlson index, Pitt score, neutropenia, source, etiology, and presentation with
severe sepsis or shock, inadequate empirical treatment was associated with increased mortality at days 14 and 30 (odds ratios
[ORs], 2.12 and 1.56; 95% confidence intervals [95% CI], 1.34 to 3.34 and 1.01 to 2.40, respectively). The adjusted ORs after a
propensity score-based matched analysis were 3.03 and 1.70 (95% CI, 1.60 to 5.74 and 0.98 to 2.98, respectively). In conclusion,
inadequate empirical therapy is independently associated with increased mortality in patients with BSI. Programs to improve
the quality of empirical therapy in patients with suspicion of BSI and optimization of definitive therapy should be implemented.
The empirical antibiotic treatment of patients with potentiallyserious infections is a challenging task. Providing appropriate
empirical coverage is proving more and more difficult as antibi-
otic resistance increases in both the hospital and the community
(1). In such situations, physicians face a dilemma: to provide a
very-broad-spectrum empirical coverage, accepting that onmany
occasions it will be excessive and might contribute to further re-
sistance selection, or to use a narrower-spectrum empirical regi-
men, accepting that it may not cover the causative pathogen and
might require correction once the susceptibility results are known
(19).
A key aspect of this decision-making process is the prognostic
impact of empirical therapy. A meta-analysis recently showed re-
ducedmortality rates for sepsis patients who received appropriate
empirical therapy (22), although the studies analyzed were heter-
ogeneous in terms of populations and types of infection covered.
In both this study and another systematic review focusing on the
methodological aspects of the topic (18), the need for new studies
with improved methodologies was outlined. Bloodstream infec-
tion (BSI) has some advantages as a model for this kind of re-
search. Although patients with bacteremia are only a subset of the
pool of patients suffering sepsis, infections are readily detectable
in routine practice, and the causativemicroorganisms and suscep-
tibility are known by definition. The objective of this study was to
assess the impact of adequate empirical therapy on the mortality
of patients with BSI in the present context of antibiotic resistance,
including methodological recommendations (18, 22).
MATERIALS AND METHODS
We followed the recommendations of the STROBE statement for report-
ing observational studies (30).
Design overview, sites, and procedures. This analysis is part of the
SAEI/SAMPAC Bacteremia Project, a project aimed at investigating the
epidemiology, clinical features, and prognosis of BSI. A prospective co-
hort study was conducted in 15 public hospitals (10 tertiary and 5 com-
munity) in Andalucía, Spain. All consecutive episodes of clinically signif-
icant BSI in adult patients (14 years old) from participating hospitals
between 15 October 2006 and 15 December 2006 (tertiary centers) or 15
March 2007 (community centers) were included in the cohort. A detailed
epidemiologic analysis of the cohort has been reported elsewhere (25).
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Episodes were detected through daily review of blood culture results.
The recommendations of the Spanish Society of Infectious Diseases and
Clinical Microbiology (SEIMC) were followed for performing, process-
ing, and interpreting the blood cultures (17). Susceptibility results were
interpreted according to Clinical and Laboratory Standards Institute
(CLSI) recommendations (6). All patients were monitored by an infec-
tious disease or internal medicine specialist at each participant hospital,
who collected the data by direct patient evaluation and by reviewing the
chart records from the date of diagnosis of BSI until discharge; for patients
discharged before day 30, mortality was assessed by consulting the elec-
tronic hospital charts and the official mortality registry. The information
was collected in a predefined structured questionnaire. The study was
approved by the ethics committee of the Hospital Universitario Virgen
Macarena, which waived the need to obtain informed consent.
Variables and definitions.Clinically significant BSIwas defined as the
isolation of a pathogen in a blood culture drawn from a patient with
sepsis, according to standard criteria (15). The day the blood cultureswere
drawn was considered to be day 0. The outcome variables were all-cause
mortality at days 14 and 30. The main exposure variable was inadequate
empirical therapy. Antimicrobials were considered empirical if they were
administered before susceptibility test results were available (typically, 48
to 72 h after blood cultures were performed) and were considered defin-
itive thereafter. Empirical therapywas considered adequatewhen all of the
following criteria were fulfilled: (i) at least one antimicrobial was admin-
istered as recommended following Spanish guidelines (5), including drug,
route, and dosage; (ii) all organisms isolated from blood were susceptible
in vitro; and (iii) the first dose was administered within the first 24 h after
the blood culture had been drawn. Otherwise, empirical therapy was con-
sidered inadequate. The decision was made by the local investigator and
reviewed by two study coordinators (Pilar Retamar and Jesús Rodríguez-
Baño), who were blinded to outcome when reviewing the data. Discrep-
ancies were solved by discussion.
Other exposure variables collected included acquisition type, classified
into hospital acquired, health care associated, or community acquired (8);
demographics; intensive care unit (ICU) admission; presence of underly-
ing chronic diseases; severity of underlying chronic conditions according
to the Charlson index (3); neutropenia (500 neutrophils perl) at day 0
(or expected to occur in3 days); source of BSI, determined from clinical
and microbiological data and using CDC criteria (12); invasive proce-
dures performed during the previous week (for major surgery, the previ-
ousmonth was considered); antimicrobial use in the preceding 2months;
severity of illness the day before the onset of bacteremia (day1), deter-
mined using the Pitt score (10); severity of systemic inflammatory re-
sponse syndrome (SIRS) on day 0, according to predefined criteria (15);
and etiology.
Statistical analysis. The associations between the different variables
andmortality were estimated by calculating crude relative risks (RR) with
95% confidence intervals (95% CI). To control for confounding, we first
performed an exploratory multivariate analysis, using logistic regression,
which included all variables related to mortality at a conservative signifi-
cance level of 0.2, plus all variables of potential clinical importance.
Variables were selected using a stepwise backward process; a P value of
0.2 was used as cutoff for keeping the variables in the model. The effect
modification between the exposure of interest and other variables was
investigated. The validity of the model was evaluated by the Hosmer-
Lemeshow test for estimating goodness of fit to the data, and its discrim-
ination ability was evaluated by using the area under the receiver operat-
ing characteristics (ROC) curve.
To further investigate the impact of inadequate empirical therapy on
mortality, we then performed a propensity score-based matched analysis
(7). The propensity score—the estimated probability (value of 0 to 1) that
a patient had received adequate empirical therapy—was calculated using a
nonparsimonious multivariable logistic regression model in which ade-
quate empirical therapy was the dependent variable and all variables with
P values of0.2 for the association with empirical therapy in the univar-
iate analysis were included as independent factors. Model validity was
assessed as explained above. Patients receiving inadequate empirical ther-
apy were matched on a 1:1 basis with patients receiving adequate empir-
ical therapy, using individual propensity scores. The matching scheme
used the minimum absolute distance between scores. The matching tol-
erance was a propensity score difference of 0.05, meaning that a patient
receiving inadequate empirical therapy was matched with one receiving
adequate empirical therapy only when the estimated probability of the
latter receiving inadequate empirical therapy lay within 5% of the esti-
mated probability of his or her counterpart receiving adequate therapy.
Whenever more than one match was possible, the selection was made by
simple randomization. Crude comparisons of the matched cohorts were
performed by the McNemar test; odds ratios (ORs) with 95% CI were
calculated by conditional logistic regression. The association between in-
adequate empirical therapy and mortality in the matched cohorts was
adjusted for other variables by using amultivariate conditional regression
logistic analysis inwhich potential confounderswere selected using a step-
wise forward process. All analyses were carried out using the SPSS 15.0
software package (SSPP Inc., Chicago, IL).
RESULTS
During the study period, 821 episodes of BSI were diagnosed in
the participating centers; 20 episodes (2.4%) were excluded be-
cause the available data were incomplete (exposure to important
variables could not be assessed in 15 cases, and postdischargemor-
tality could not be assessed in 5 cases). Thus, 801 episodes in 756
patients were included (Fig. 1). Inadequate empirical therapy was
administered in 199 episodes (24.8%). The characteristics of the
patients are shown in Table 1, listed according to adequate or
inadequate empirical therapy. All-causemortality was 18.5% (148
patients) at day 14 and 22.6% (181 patients) at day 30.
Table 2 shows the crude analysis of the associations between
exposure to different variables and 14-day mortality. The associ-
ations between the various sources and etiologies of BSI andmor-
tality are shown in more detail in Table 3. Since mortality rates
associated with the biliary tract, the urinary tract, and use of a
vascular catheter were similar and also significantly lower than
that associated with other sources, the variable “source” was di-
chotomized into low-risk (including those mentioned above) and
FIG 1 Patients with BSI included in the cohort, with mortality shown accord-
ing to antimicrobial therapy.
Empirical Therapy in Bacteremia
January 2012 Volume 56 Number 1 aac.asm.org 473
high-risk sources. Furthermore, since mortality rates associated
with monomicrobial episodes caused by Klebsiella spp., Esche-
richia coli, and coagulase-negative staphylococci were similar and
also lower than that caused by other microorganisms or polymi-
crobial episodes, etiology likewise was dichotomized into low-
and high-risk etiologies. The mortality rate of patients receiving
inadequate empirical therapy was higher than that of patients re-
ceiving adequate empirical therapy (Table 2).
Overall, infections caused by methicillin-resistant Staphylococcus
aureus, extended-spectrum-beta-lactamase (ESBL)-producingE. coli
or Klebsiella, or carbapenem-resistant Pseudomonas aeruginosa or
Acinetobacter baumanniiwere associatedwith an increased crude risk
of 14-daymortality comparedwith infections causedby their suscep-
tible counterparts (17/78 episodes [21.7%] versus 31/324 episodes
[9.5%]; RR 2.28 [95%CI 1.33 to 3.90]; P 0.002).
The univariate analysis of variables potentially associated with
mortality at day 30 showed similar results for most variables (data
not shown); however, there was no significant difference in mor-
tality between patients receiving adequate and inadequate empir-
ical therapies (26.4% versus 21.4%; RR 1.21 [95% CI 0.92 to
1.61]; P 0.1).
Among the 199 patients who received inadequate empirical
therapy, 11 died before the susceptibility test results were available
(Fig. 1). Of the 188 patients who survived until then, definitive
therapy was delayed48 h after the susceptibility test results were
available for 77 patients, and 111 patients were changed to an
TABLE 1 Features of 801 episodes of bloodstream infections, according to adequate or inadequate empirical therapy
Characteristic
Valuea
P valueb
Inadequate empirical
therapy (n 199)
Adequate empirical
therapy (n 602)
Hospital-acquired infection 142 (71.4) 318 (52.8) 0.001
Male gender 116 (58.3) 357 (59.3) 0.8
Median age (yr) (interquartile range) 67 (56–76) 66 (51–75) 0.3
Tertiary hospital 154 (77.4) 483 (80.2) 0.3
ICU admission 43 (21.6) 1112 (18.6) 0.3
Median Charlson index (interquartile range) 2 (1–4) 2 (1–3) 0.2
Median Pitt score (interquartile range) 1 (0–3) 1 (0–3) 0.9
Cancer 67 (33.7) 160 (26.6) 0.05
Diabetes mellitus 48 (24.1) 159 (26.4) 0.5
Chronic pulmonary disease 25 (12.6) 80 (13.3) 0.7
Chronic renal insufficiency 20 (10.1) 70 (11.6) 0.5
Chronic liver disease 18 (9) 55 (9.1) 0.9
Neutropenia 9 (4.5) 37 (6.1) 0.3
Central venous catheter 77 (38.7) 168 (27.9) 0.004
Urinary catheter 81 (40.7) 195 (32.4) 0.03
Mechanical ventilation 28 (14.1) 66 (11) 0.2
Parenteral hyperalimentation 18 (9) 26 (4.3) 0.01
Previous antimicrobial use 98 (49.2) 231 (38.5) 0.008
Surgery 39 (19.6) 75 (12.5) 0.01
Source of bacteremia 0.002
Unknown 55 (27.6) 135 (22.4)
Urinary tract 23 (11.6) 137 (22.8)
Intra-abdominal infection 29 (14.5) 110 (18.2)
Vascular catheter 51 (25.6) 82 (13.6)
Respiratory tract 25 (12.6) 77 (12.8)
Other source 16 (8) 61 (10.1)
Etiology 0.001
Escherichia coli 34 (17) 188 (31.2)
Coagulase-negative staphylococci 60 (30.1) 78 (12.9)
Staphylococcus aureus 24 (12) 74 (12.2)
Klebsiella pneumoniae 13 (6.5) 58 (9.6)
Enterococcus spp. 21 (10.5) 38 (6.3)
Streptococcus pneumoniae 3 (1.5) 36 (5.9)
Pseudomonas aeruginosa 11 (5.5) 28 (4.6)
Enterobacter spp. 9 (4.5) 18 (2.9)
Acinetobacter baumannii 13 (6.5) 10 (1.6)
Other 34 (17) 109 (18.1)
Polymicrobial etiology 23 (11.6) 35 (5.8) 0.007
Severe sepsis or septic shock 42 (21.1) 165 (25.9) 0.07
a Data are expressed as numbers (percentages) of cases, except where specified.
b P values were calculated using the chi-square test, except for age, Charlson index, and Pitt score (Mann-Whitney U test).
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active antimicrobial in less than 48 h. The 14-daymortality among
patients with delayed definitive therapy was 29.9%, compared to
13.5% among those whose therapy was not delayed (RR  2.21
[95% CI  1.24 to 3.96]; P  0.006), and 30-day mortality rates
were 29.9% and 16.2%, respectively (RR 1.84 [95%CI 1.07 to
3.17]; P 0.02).
An exploratory multivariate analysis of variables associated
with 14- and 30-day mortality was then performed. The variables
introduced were age, type of acquisition, type of hospital, Charl-
son index, neutropenia, Pitt score, ICU admission, severity of
SIRS at presentation, source, etiology, and empirical therapy. The
interactions between empirical therapy and source, etiology, and
severity of SIRSwere also studied. All variables were dichotomized
with the aim of simplifying interpretation. Table 4 presents the
data for the final models. Inadequate empirical therapy was asso-
ciated with an increased risk of death at days 14 and 30 after con-
trolling for age, Charlson index, neutropenia, source, etiology, Pitt
score, and severity of SIRS at presentation. Pitt score and age were
kept in both final models (14- and 30-day mortality) even if they
were not significantly associated in one of them because they were
important in the other; removing them frommodels in which no
significant associationwas found did not change the results. The P
value for the Hosmer-Lemeshow goodness-of-fit test was 0.69 for
the 14-day mortality model and 0.21 for the 30-day mortality
TABLE 2 Univariate analysis of associations between exposure to
different variables and 14-day mortality in 801 episodes of
bloodstream infection
Variable
Mortality at 14 days
(no. of deaths/no.
of infections [%]) RR (95% CI) P valuec
Gender
Male 96/473 (20.3) Reference
Female 52/318 (15.9) 0.71 (0.57–1.06) 0.1
Age (yr)
55 25/204 (12.3) Reference
55 123/597 (20.6) 1.68 (1.13–2.51) 0.007
Type of acquisition
Community 22/149 (14.8) Reference
Health care associated 34/192 (17.7) 1.20 (0.73–1.96) 0.4
Hospital 92/560 (20) 1.35 (0.88–2.08) 0.1
Type of hospital
Tertiary 112/637 (17.6) Reference
Community 36 (164 (22.0) 1.25 (0.89–1.74) 0.1
Charlson index
0–1 42/334 (12.6) Reference
2 41/212 (19.3) 1.54 (1.04–2.28) 0.03
3 65/255 (25.5) 2.03 (1.52–3.74) 0.001
Neutropenia
No 133/755 (17.6) Reference
Yes 15/46 (32.6) 1.85 (1.19–2.88) 0.01
Pitt score
0-1 47/491 (9.6) Reference
2 15/92 (16.3) 1.70 (1.00–2.91) 0.05
3 86/218 (39.4) 4.12 (3.00–5.66) 0.001
ICU admission
No 90/646 (13.9) Reference 0.001
Yes 58/155 (37.4) 2.69 (2.03–3.55)
Severity of SIRS at
presentation
Sepsis 62/594 (10.4) Reference
Severe sepsis 37/100 (37.0) 3.16 (2.19–4.56) 0.001
Septic shock 53/107 (49.5) 4.75 (3.50–6.43) 0.001
Sourcea
Low risk 36/352 (10.2) Reference
High risk 112/449 (24.9) 2.44 (1.72–3.46) 0.001
Etiologyb
Low risk 48/386 (24.1) Reference
High risk 100/415 (24.1) 1.94 (1.41–2.66) 0.001
Empirical therapy
Adequate 99/602 (16.4) Reference
Inadequate 49/199 (24.6) 1.47 (1.10–2.02) 0.01
a Low-risk sources include the biliary tract, urinary tract, and vascular catheter. For
further explanation, see the text and Table 3.
b Low-risk etiology includes monomicrobial episodes caused by Klebsiella spp.,
Escherichia coli, and coagulase-negative staphylococci. For further explanation, see the
text and Table 3.
c P values were calculated by the chi-square test.
TABLE 3Mortality at day 14 in patients with bacteremia, according to
source of infection and etiology
Variable
Mortality at 14
days (no. of
deaths/no. of
infections
[%]) RR (95% CI) P valuea
Source
Biliary tract 5/59 (8.5) Reference
Urinary tract 16/160 (10.0) 1.18 (0.45–3.08) 0.7
Vascular catheter 15/133 (11.3) 1.33 (0.51–3.49) 0.5
Unknown source 40/190 (21.1) 2.48 (1.03–6.00) 0.02
Intra-abdominal infectionb 24/80 (30.0) 3.54 (1.44–8.73) 0.002
Respiratory tract 33/102 (32.4) 3.82 (1.58–9.24) 0.001
Other 15/77 (24.1) 2.30 (0.89–5.97) 0.07
Etiologyc
Klebsiella spp. 5/60 (8.3) Reference
Escherichia coli 24/203 (11.8) 1.42 (0.57–3.56) 0.4
Coagulase-negative
staphylococci
19/123 (15.4) 1.85 (0.73–4.72) 0.1
Streptococcus pneumoniae 9/37 (18.9) 2.92 (1.06–8.04) 0.02
Staphylococcus aureus 19/95 (20.0) 2.40 (0.95–6.09) 0.05
Enterobacter spp. 6/23 (26.1) 3.13 (1.06–9.27) 0.03
Enterococcus spp. 11/40 (27.5) 3.30 (1.24–8.78) 0.01
Pseudomonas aeruginosa 10/32 (31.3) 3.75 (1.40–10.03) 0.004
Other microorganisms 27/130 (20.7) 2.49 (1.01–6.15) 0.03
Polymicrobial bacteremia 18/58 (31.0) 3.72 (1.48–9.37) 0.001
Antimicrobial resistanced
Multidrug resistant 25/112 (22.3) 1.25 (0.85–1.83) 0.2
Not multidrug resistant 123/689 (17.9) Reference
a P values were calculated by the chi-square test.
b Other than the biliary tract.
c Only monomicrobial episodes were considered for each specific microorganism.
d Includes methicillin-resistant S. aureus, extended-spectrum-beta-lactamase-producing
enterobacteria, and all meropenem- or imipenem-resistant Gram-negative bacilli.
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model. The areas under the ROC curves were 0.79 and 0.76, re-
spectively. Inclusion of specific etiologies or sources in themodels
did not significantly change the impact of inappropriate empirical
therapy. A conditional analysis which included the participating
hospitals disclosed similar results (data not shown).
We next used propensity score analysis to further adjust for
confounding. Type of service, type of acquisition, a diagnosis of
cancer, use of a central venous catheter, use of a urinary catheter,
parenteral hyperalimentation, surgery, previous antimicrobial
use, BSI source, and severity of SIRS at presentation showed crude
P values of0.2 in association with inadequate empirical therapy
(Table 1) and were introduced into a nonparsimonious multivar-
iate logistic regression model (etiology was not considered, since
this factor is unknownwhen empirical therapy is indicated). TheP
value of the Hosmer-Lemeshow test for the model was 0.67, and
the area under the ROC curve was 0.78. One hundred ninety-one
pairs of patients were matched according to their probability of
receiving inadequate empirical therapy according to this model.
Pairs were matched suitably by age, gender, type of acquisition,
ICU admission, Charlson index, underlying diseases, invasive
procedures, previous antimicrobial use, BSI source, Pitt score, and
severity of SIRS at presentation (Table 5). Eight patients with in-
adequate treatment (4%) could not be matched because of the
preestablished cutoff for matching tolerance. Mortality at day 14
was 24.6% (47 patients) for those with inadequate empirical ther-
apy and 11.0% (21 patients) for those who received adequate ther-
apy; at day 30, mortality was 26.2% (20 patients) and 17.3% (31
patients) for those with inadequate and adequate empirical ther-
apy, respectively. With respect to the 191 matched pairs, both
members of the matched pair survived for 14 days in 135 cases,
and both died in 12 cases; the patient who received inadequate
empirical therapy died and the matched counterpart survived in
35 cases; and the opposite occurred in 9 cases. The corresponding
data for 30-day mortality were 128, 20, 30, and 13 pairs, respec-
tively. ORs (95% CI) calculated by conditional logistic regression
were 3.58 (1.86 to 8.0) and 2.0 (1.07 to 3.71) for 14- and 30-day
mortality, respectively, and P values obtained using McNemar’s
test were0.001 and 0.02, respectively. Conditional multivariate
analysis showed that inadequate empirical therapy was associated
with 14-day mortality when controlling for source, etiology, Pitt
score, and severity of SIRS at presentation; the adjusted OR (95%
CI)was 3.03 (1.60 to 5.74) (P 0.001). The adjustedOR (95%CI)
for 30-daymortality obtainedusing the samemodelwas 1.70 (0.97
to 2.98) (P 0.06).
Table 6 shows the associations between inadequate empirical
therapy andmortality for all analyses. In the case of crude analysis,
we included ORs instead of RRs to facilitate comparison.
Themost frequent empirical regimens usedweremonotherapy
with a -lactam (343 patients [42.8%]) or fluoroquinolone (74
patients [9.2%]) or combination therapy with a -lactam plus a
fluoroquinolone (99 patients [12.3%]), a -lactam plus a glyco-
peptide (78 patients [9.7%]), or a -lactam plus an aminoglyco-
side (47 patients [5.8%]). Overall, combination therapy was asso-
ciated with a higher probability of appropriate empirical therapy
than monotherapy (80.1% versus 72.3%; crude RR  1.11 [95%
TABLE 4 Final logistic regression model for exploratory multivariate
analysis of variables associated with mortality in patients with
bloodstream infections
Variable  coefficient OR (95% CI) P value
Mortality at day 14
Age of55 yr 0.62 1.86 (1.10–3.15) 0.02
Charlson index of2 0.63 1.88 (1.21–2.92) 0.005
Neutropenia 0.76 2.14 (0.99–4.65) 0.05
High-risk source 0.84 2.32 (1.46–3.67) 0.001
High-risk etiology 0.53 1.71 (1.11–2.63) 0.01
Pitt score of2 0.35 1.42 (0.81–2.51) 0.21
Severe sepsis or septic shock
at presentation
1.49 4.45 (2.51–3.34) 0.001
Inadequate empirical therapy 0.75 2.12 (1.34–3.34) 0.001
Mortality at day 30
Age of55 yr 0.36 1.45 (0.92–2.28) 0.11
Charlson index of2 0.49 1.64 (1.10–2.44) 0.01
Neutropenia 0.62 1.86 (0.88–3.91) 0.09
High-risk source 0.79 2.21 (1.45–3.35) 0.001
High-risk etiology 0.65 1.91 (1.29–2.84) 0.001
Pitt score of2 0.67 1.96 (1.18–3.23) 0.009
Severe sepsis or septic shock
at presentation
1.09 2.93 (1.76–4.99) 0.001
Inadequate empirical therapy 0.44 1.56 (1.01–2.40) 0.04
TABLE 5 Comparison of matched patients receiving inadequate and
adequate empirical therapya
Variable
No. (%) of patients
P value
Inadequate
empirical
therapy
(n 191)
Adequate
empirical
therapy
(n 191)
Male gender 110 (57.6) 123 (64.4) 0.1
Age of55 yr 148 (77.5) 140 (73.3) 0.3
Tertiary center 149 (78.0) 156 (81.7) 0.3
ICU admission 41 (21.5) 46 (24.1) 0.4
Nosocomial BSI 134 (70.2) 133 (69.6) 0.9
Charlson index of2 116 (60.7) 111 (58.1) 0.4
Cancer 65 (34.0) 66 (34.6) 1.0
Central venous catheter 73 (38.2) 66 (34.6) 0.5
Parenteral hyperalimentation 16 (8.4) 17 (8.9) 0.6
Surgery 36 (18.8) 40 (20.9) 0.4
Previous antimicrobial
treatment
92 (48.2) 94 (49.2) 0.8
High-risk etiology 102 (53.4) 97 (50.8) 0.4
High-risk source 110 (57.6) 110 (57.6) 1.0
Pitt score of2 74 (38.7) 66 (34.6) 0.6
Presentation with severe
sepsis or septic shock
38 (21.6) 31 (17.3) 0.3
Mortality at day 14 47 (24.6) 21 (11.0) 0.001
Mortality at day 30 50 (26.2) 33 (17.3) 0.02
a Patients were matched using a propensity score. P values were calculated by the
McNemar test.
TABLE 6 Odds ratios and 95% confidence intervals for inadequate
empirical therapy and mortality
Cohort
OR (95% CI)
14-day mortality 30-day mortality
Complete, crude 1.66 (1.13–2.50) 1.29 (0.84–1.88)
Complete, adjusted 2.12 (1.34–3.34) 1.56 (1.01–2.40)
Matched 3.58 (1.86–8.0) 2.0 (1.07–3.71)
Matched, adjusted 3.03 (1.60–5.74) 1.70 (0.97–2.98)
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CI 1.02 to 1.20]; P 0.001), although mortality rates at day 14
or 30 did not differ significantly (22% versus 16.5% for day 14
[RR 1.29 {95% CI 0.96 to 1.73}; P 0.1] and 25.8% versus
20.9% for day 30 [RR 1.24 {95% CI 0.95 to 1.60}; P 0.1]).
DISCUSSION
Our data showed that receipt of inadequate empirical therapy was
independently associatedwith increasedmortality in patientswith
BSI. It was estimated that patients who received inadequate em-
pirical therapy had an adjusted 2-fold greater probability of dying
by day 14; the results of the propensity score-based matched co-
horts showed even higher ORs. As expected, the magnitude of the
association was lower for 30-day than for 14-daymortality, mean-
ing that the impact of adequate therapy is higher on early mortal-
ity. Since BSI affects between 100 and 200 people per 100,000
population-year and the incidence seems to be increasing (24, 25,
28), these results are relevant for the management of patients.
Our results are consistent with those of a recent meta-analysis
which analyzed the impact of appropriate empirical therapy on
patients with sepsis (22). The nature of the studies included in the
meta-analysis was heterogeneous, and many considered only cer-
tain types of patients, infections, or microorganisms. Definitions
of inadequate therapy also varied, withmostly only in vitro activity
being considered. The need for new studies using improvedmeth-
odology to analyze the association between antibiotic therapy and
mortality has been outlined (18, 22), with specific recommenda-
tions that (i) empirical and definitive therapies should be assessed
separately; (ii) the definition of adequate therapy should include
in vitro susceptibility data, dosage, and route and pattern of ad-
ministration, rather than considering only in vitro activity (for
which the term “appropriate” is frequently used); (iii) the results
should be adjusted according to the severity of the patient’s illness
(see below); (iv) the results should be reported according to the
STROBE recommendations (30); and (v) mortality should be as-
sessed at day 30 (22) or in a manner that best represents the
underlying construct within the biologically plausible window of
effect (18). Taking this into account, we analyzed both early (14-
day) and late (30-day) mortality; our results suggest that 14-day
mortality might be an adequate time frame for evaluating the im-
pact of antimicrobial therapy in patients with BSI, since latermor-
tality may be influenced more by other conditions. Our study
provides data for patients with BSI irrespective of the etiology,
acquisition type, source, patient characteristics, or service re-
ceived. Other strengths of our study are its prospective and mul-
ticenter nature.
With regard to controls for confounding potentially caused by
the severity of the patient’s illness, we assessed both the severity of
chronic underlying conditions, using the Charlson comorbidity
index, and the acute severity of the illness the day before the onset
of bacteremia, using the Pitt score, both of which have been used
extensively asmortality predictors for patients with BSI and sepsis
(2, 4, 10, 11, 14, 20, 23, 26, 27).We did not usemore sophisticated
scores, such as the APACHE II score, because much of the data
required to calculate it are not available for non-ICU patients.
There is controversy about the convenience of controlling for the
severity of SIRS at presentation. Some authors consider this an
intermediate variable (18), but we agree with others that it is an
intermediate variable only for analyzing a prognosis associated
with the causative microorganism, not for evaluating the impact
of empirical therapy, since empirical therapy is administered after
severe sepsis or shock has developedwhenever the severity of SIRS
is measured at presentation (22, 29). Other variables found to be
predictors of mortality in our study included age, neutropenia,
source, and the etiology of BSI. We think that it is crucial to con-
trol for these variables in future studies concerning the prognosis
of BSI.
Beyond controlling for confounding by using multivariate
analysis, we also used a propensity score-based analysis (7). As far
as we know, this technique has been used in 4 previous studies to
analyze the impact of empirical therapy. In 2 of these, the propen-
sity score for each patient’s likelihood of receiving inadequate em-
pirical therapy was introduced into the multivariate models. Har-
barth et al. found inadequate empirical therapy to be associated
with increased 28-daymortality in 904 patients withmicrobiolog-
ically documented severe sepsis or shock (468 had bacteremia)
(9). Lin et al. found that delaying active antimicrobial treatment
was associated with increased 30-day mortality in bacteremic pa-
tients with severe neutropenia (16). Two other studies used the
propensity score to conduct a matched cohort analysis. Kim et al.
did not find that appropriate empirical therapywas independently
associated with increased mortality after 12 weeks of follow-up in
238 patients with BSI due to S. aureus (13), although the statistical
power of the study was limited. Paul et al. studied 920 patients
with microbiologically documented infections, and by multivari-
ate analysis, appropriate empirical therapy was associated with
decreased 30-daymortality (OR, 0.63; 95%CI, 0.39 to 1.01); how-
ever, in the propensity-matched cohort (574 patients), theORwas
0.75 (95% CI, 0.44 to 1.27) (21). The mortality rate in that series
was 14.3%, much lower than that in our study, which is probably
explained by the fact that only 39.5% of patients were bacteremic.
Our study has some limitations. We cannot rule out the influ-
ence of unmeasured variables. The efficacies of the different em-
pirical antibiotic regimens may not have been homogeneous. We
did not measure other outcome variables, such as duration of
hospital stay or the ecological impact of superfluous empirical
regimens. The data were obtained in a relatively short time and
reflect sepsis and BSI treatment practices in one part of Spain in
2006-2007 that may not be the same in other parts of the world.
Finally, even though antibiotic therapy is considered a key aspect
in the management of patients with sepsis, inadequate empirical
therapymight be just a surrogatemarker for poor quality of care of
patients with sepsis.
These results emphasize the importance of providing early ad-
equate empirical therapy to all patients suspected of BSI. To
achieve this, several conditionsmust bemet (24). First, patients at
risk of BSI must be recognized promptly. Second, features that
may influence the etiology of infection should be assessed, includ-
ing the patient’s predisposing conditions, the severity of SIRS, and
the potential source of infection. Third, appropriate antibiotic
guidelines, adapted to the local epidemiology, must be followed.
Finally, whenever empirical therapy is found to be inadequate or
superfluous, treatment should be adjusted as soon as possible.We
recently proposed some quality indicators that would be useful in
analyzing the impact of interventions aimed at improving the
management of patients with bacteremia (24).
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